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xABSTRACT
Sridhar, Akshayalakshmi. M.S., Purdue University, August 2012. Transcriptional
Regulation of Retinal Progenitor Cells Derived from Human Induced Pluripotent
Stem Cells. Major Professor: Jason Meyer.
In order to develop effective cures for diseases and decipher disease pathology, the
need exists to cultivate a better understanding of human development. Existing
studies employ the use of animal models to study and model human development
and disease phenotypes but the evolutionary differences between humans and other
species slightly limit the applicability of such animal models to effectively recapitulate
human development. With the development of human pluripotent stem cells (hPSCs),
including Human induced Pluripotent stem cells (hiPSCs) and Human Embryonic
Stem cells (hESCs), human development can now be mirrored and recapitulated in
vitro. These stem cells are pluripotent, that is, they possess the potential to generate
any cell type of the body including muscle cells, nerve cells or blood cells. One of
the major focuses of this study is to use hiPSCs to better understand and model
human retinogenesis. The retina develops within the first three months of human
development, hence rendering it inaccessible to investigation via traditional methods.
However, with the advent of hiPSCs, retinal cells can be generated in a culture dish
and the mechanisms underlying the specification of a retinal fate can be determined.
Additionally, in order to use hiPSCs for successful cell replacement therapy, non-
xenogeneic conditions need to be employed to allow for fruitful transplantation tests.
Hence, another emphasis of this study has been to direct hiPSCs to generate retinal
cells under non-xenogeneic conditions to facilitate their use for future translation
purposes.
11. INTRODUCTION
1.1 Retina and its function
The human retina is the part of the eye that allows for the ability to visualize ob-
jects. The visual information received by the eye is converted into electrical stimuli
by the retina, which are then interpreted by the brain to perceive the objects in front
of us. As a result, diseases such as retinitis pigmentosa, macular degeneration and
cone-rod dystrophy damage the retina, in turn affecting our vision. Upon remaining
undiagnosed, these diseases result in severe phenotypes, ultimately leading to blind-
ness. Hence, efforts are being made to understand the development of retina and its
functioning to develop successful treatments for these diseases. In order to do so, one
needs to have a clear understanding of the structure of the retina and its development.
The retina is derived from central nervous system and is located towards the back
of the eye (Figure 1.1A). It is an organized structure composed of six types of cells:
photoreceptors consisting of rods and cones, muller glia cells, horizontal cells, bipolar
cells, amacrine cells and ganglion cells (Figure 1.1B). These cells are arranged in spe-
cific layers, with the photoreceptor layer being the outermost and the ganglion cells
are the innermost. In between these two layers lie the inner nuclear layer consisting of
horizontal cells, bipolar and the amacrine cells. Intermingled in these layers are the
inner plexiform layer and the outer plexiform layer, which help the inner nuclear area
form connections with the ganglion cells and the photoreceptors respectively [2, 3].
The photoreceptors are embedded in the Retinal Pigmented Epithelium (RPE), which
2supports and provides nourishment to the photoreceptors. The organization of the
retina into such layers forms a highly regulated pathway to encode the visual infor-
mation in the form of synapses which are then carried to the brain [4].
Figure 1.1. [1] Schematic illustration of the human eye and the location
of the retina (A). Representation of the different layers of retina (B).
When light reaches the eye, it is focused by the lens and is sent to the back of the eye,
where the retina is located. In the retina, photoreceptors convert the visual input to
electrical stimuli/neuronal signals which can be processed by the brain. This infor-
mation is then passed via the bipolar cells to the retinal ganglion cells which carry
the information from the eye to specific regions of the brain such as the tectum and
the lateral geniculate nucleus via the optic nerve. The results of this pathway help
see the object in front of us [5].
Hence, the retina is a highly specialized yet accessible structure which delivers the
power of sight. An effort to understand this complex machinery is incomplete without
an understanding of how the retina is specified. Therefore, a thorough understanding
of the development of the retina is crucial to comprehend its specification.
31.2 Retinal development
The development of the retina is a direct consequence of eye development from the
primitive anterior neuroectoderm (Figure 1.2). Eye development is initiated after
the process of neurulation, which involves the folding of the neural plate to form the
neural tube. As a result of this process, optic grooves form on either side of the devel-
oping forebrain. These optic grooves start to evaginate toward the surface ectoderm,
forming optic vesicles at the end of the neurulation process. Optic vesicles continue to
evaginate until it comes close to the head ectoderm, leading to the induction of head
ectoderm to form the lens placode. Retinal specification begins after the formation
of lens placode, where the lens placode induces the distal regions of the optic vesicle
to form the retina while the surrounding mesenchyme induces the formation of RPE
from the proximal regions of the optic vesicle [6, 7]. The spatio-temporal location of
the retina and its development is governed by a mixture of growth factors such as
SHH (Sonic Hedghog), WNT signaling and Fibroblast Growth Factor (FGF), as well
as transcription factors such as Otx2, Pax6, Six3, Six6 and Rax [8].
4Figure 1.2. [6] Schematic representation of different stages involved in the
development of the vertebrate retina.
In general, the specification of different cell types in the nervous system, including
the neural retina, is facilitated by both extrinsic and intrinsic factors [9]. Some
studies have indicated that the specification of different cell types is governed by
competence model, which suggests that different cell types arise depending on the
competence stage of the progenitor cell [10]. With respect to the retina, differentiation
of these retinal cell types is thought to be accomplished by a combination of basic
helix-loop-elix (bHLH) factors such as Math5 and Neuro-D, families of transcription
factors, as well as homeobox genes such as Pax6 and Six3 [11]. These homeobox
genes, along with other transcription factors which were reported to play a major
5role in eye development, were grouped together and are collectively known as Eye
Field Transcription Factors (EFTFs) [12, 13]. These factors are expressed in specific
patterns within the anterior neural plate at very early stages and play an important
role in the development and specification of the eye.
1.3 Eye field transcription factors
EFTFs comprise of a group of seven transcription factors, namely pax6, rax, six3,
six6, nr2e1(tll), lhx2 and tbx3(et) [12,14]. Most of the EFTFs were first discovered in
Drosophila and previous studies have indicated that these EFTFs highly conserved
among different species [15]. They function via a series of multifaceted and reciprocal
process of signaling in order to specify the timing as well as the location of the eye
during its development. Previous studies performed in model systems such as Xeno-
pus have helped to shed light on the highly dynamic and overlapping patterns of
expression of these EFTFs [12]. These EFTFs are expressed in a highly coordinated
manner in the developing anterior neural plate of Xenopus (Figure 1.3). Comparison
of the expression patterns of EFTFs at stage 12.5/13 and stage 15 of Xenopus devel-
opment indicates the expression patterns of EFTFs as they trace the eye field upon
separation from the neural plate.
The expression of EFTFs is preceded by the expression of a forebrain and midbrain
transcription factor otx2. Initially, otx2 is expressed throughout the primitive an-
terior neuroepithelium [16, 17]. However, following neurulation, otx2 expression is
downregulated towards the epicenter and a void is created, making way for the ex-
pression of the EFTFs [12]. It has been demonstrated OTX2 expression is restricted
to optic vesicle and RPE at later stages of the developing chick embryo [18]. Studies
6have suggested that the downregulation of otx2 is triggered by the activation of rax,
a transcription factor which is also a part of the EFTF network, suggesting the es-
tablishment of the eye field in this region [155]. At this stage, the EFTFs are thought
to activate each other and function in a coordinated and overlapping manner leading
to the development of eyes in this region.
Figure 1.3. [12] Schematic illustration of the overlapping patterns of ex-
pression of EFTFs in Xenopus at two different stages of its development.
Studies have indicated the expression of EFTFs is necessary and sufficient for retinal
fate specification. Injection of these EFTFs (minus lhx2 ) in the two cell stage of
the Xenopus embryo led to the endogenous activation of lhx2 and development of
ectopic eyes [12]. This suggests that these EFTFs activate each other and function in
a very complex, yet remarkably synchronized manner to induce eyes. Pax6, which is
a part of the EFTF network has been demonstrated to be a fate determinant for the
neuroectoderm and also plays a prominent role in determining the phenotypic fate of
retinal progenitor cells [20, 21]. Furthermore, misexpression of pax6 has been shown
to generate ectopic eyes in Drosophila and Xenopus [22, 23].
Overexpression of EFTFs including Pax6, Rax, Six3 and Six6 in lower vertebrate
systems have led to the expansion of the retinal territory, generation of large eyes
or the formation of ectopic RPE [24–28]. Deletion or knockouts of EFTFs like Rax
7and Lhx2 in mouse have been known to cause anopthalmia or a lack of eye forma-
tion [26, 29]. Malformations in the eyes have been observed in Drosophila owing to
mutations of pax6, six3, six6 [30]. Also, mutations in Lhx2, Pax6, Nr2e1 and Rax in
lower model systems have produced severe phenotypes with abnormal eyes or no eyes
at all. [26,29,31,32]. Hence, each EFTF has been reputed to play a significant role in
the development of the eye. The roles of these EFTFs might also be linked to their
pattern of expression; some EFTFs such as pax6, rax and et are expressed earlier
in eye development where as some other factors such as tll and six6 are expressed
later [12,13]. This further illustrates the governance of the timing of eye development
by EFTFs.
In all, these studies help establish the essential role of EFTFs in development of
the eye. However, the precise role of EFTFs in specifying a retinal fate has not
been studied in detail. Secondly, though their patterns of expression have been well
characterized in lower model systems such as Xenopus and mouse, studies related to
the characterization of EFTFs in humans and their role in the retinal specification
have been largely non-existent due to a lack of an appropriate model.
1.4 Limitation of retinal developmental studies in humans
Studies related to retinal development in humans have been limited due to two main
reasons: First, athough animal models such as Xenopus, zebrafish and mouse have
provided a foundation upon whch we have been better able to understand human de-
velopment, the evolutionary differences between humans and other vertebrates may
occasionly limit the applicability of these studies to be translated to a human sys-
tem [33]. For instance, the development of a mouse from an embryo takes only three
weeks whereas humans have a long gestation period of nine months [34–36]. Also,
though the homeobox genes have been conserved across most species, their patterns
of expression differ from one species to another. For instance, in mouse, Sox1 is
8expressed before Pax6 whereas in humans, the reverse order is followed [21]. Fur-
thermore, animal models have certain limitations in their ability to model human
diseases. Studies have suggested using rat models to model diseases like macular
degeneration [37,38]. However, mice and other lower vertebrates do not possess mac-
ula in the eye, which affects their ability to effectively serve as a model system to
map diseases like age related macular degeneration [39, 40]. Furthermore, rodents
have been demonstrated to possess a higher ratio of rods to cones than primate coun-
terparts, thus underscoring further differences between these models and humans [41].
Secondly, eye development occurs very early in humans, specifically, during the first
trimester of human embryogenesis [42, 43]. This raises significant ethical issues for
isolating and culturing the embryos at this stage. Some labs have cultured adult fetal
tissues and expanded them in vitro to form photoreceptor cells. However, only 30%
of the cells from this culture system exhibited a photoreceptor like morphology [44].
Also, these cells do not possess the innate ability to be cultured indefinitely without
changes in the differentiation ability of these cells. Furthermore, from a human fetal
source, cellular material tends to be highly limited in abundance.
Hence, the need exists to develop a model system that not only recapitulates early
developmental events in humans that would otherwise be inaccessible to investigation
but also offers distinct technical advantages when compared to traditional methods.
The advent of human pluripotent stem cells (hPSCs), including both human embry-
onic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), helps
overcome some of the disadvantages associated with traditional model systems such
as Xenopus or mouse and hence, serve as powerful in vitro models for studies of
human development and disease.
91.5 Human induced Pluripotent Stem Cells (hiPSCs)
Stem cells have always received attention from the medical field due to their ability
to self-renew and differentiate into cell types of various lineages such as blood cell,
nerve cells or muscle cells [45]. In humans, adult stem cells are found in limited areas
of the body such as mesenchymal stem cells of the bone marrow or neural stem cells
of the hippocampus [46]. It has been demonstrated that these cells are multipotent
and can generate cells of their particular cellular lineage. The restricted self-renewal
capabilities of these cells coupled with the small sample number of these cells in vivo
have encouraged scientists to look for other potential sources of stem cells. The umbi-
cal cord and amniotic fluid are other potential sources of stem cells for regenerative
medicine but are not pluripotent in nature [47–49]. However, the first major break-
through was achieved in 1981 when mouse embryos were first cultured on a culture
dish [50]. It was shown that pluripotent stem cells could be isolated from these mouse
embryos and the term ‘embryonic stem cell’ was coined [51]. This technique was ap-
plied to humans, producing human embryonic stem cell lines using embryos donated
from in vitro fertilization clinics [52].
An effort to eliminate the embryonic source of these stem cells was realized through
the advent of hiPSCs. These cells were described in 2007 by two groups of lead-
ing researchers- Shinya Yamanaka’s team at Kyoto University in Japan and James
Thomson at the University of Wisconsin-Madison [53, 54]. Through the introduc-
tion of retroviruses encoding pluripotency-associated genes into human skin fibrob-
lasts, they were able to reprogram fibroblasts into cells resembling hESCs. Since
2007, hiPSCs have been implicated to hold great potential in the field of regenerative
medicine [45,55].
hiPSCs offer several advantages: Firstly, they are pluripotent by definition, meaning
that they can give rise to any adult stem cell type of the human body such as muscle
cell or blood cells [53,56]. Secondly, these cells have been derived by reprogramming
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adult somatic cells; unlike embryonic stem cells, which were derived from inner cell
mass of the blastocyst stage of an embryo [54]. Thirdly, these cells have been demon-
strated to recapitulate the blastocyst stage of human development; thus they serve
as excellent model to mirror early stages of human development that are otherwise
inaccessible to investigation [57]. And lastly, it has been shown that these cells can be
directed to differentiate to form different mature cell types like blood cells, neurons or
muscle cells [58,59,61]. Owing to these unparalleled advantages, hiPSCs were chosen
to serve as an in vitro model to map human retinogenesis in the Meyer lab. Hence
we seek to use hiPSCs as a model to study and decipher the complexities of retinal
development.
1.6 hiPSCs and Regenerative medicine
hiPSCs have been implicated to hold great potential for regenerative medicine. The
non-embryonic source of hiPSCs has made it possible to generate pluripotent stem
cells from almost any cell type of the body. The advent of non-viral reprogramming
vectors and the use of non-xenogeneic techniques have helped promote hiPSCs as
an important tool in regenerative medicine [60, 164]. As a result, hiPSCs have been
implicated to serve as a critical tool for cell replacement [62, 63, 107]. A successful
demonstration of this technique was illustrated in a study performed on humanized
sickle-cell anemic mouse [64]. iPS cells were derived from an affected mouse and
the gene defect was identified and corrected using gene-specific targeting. These cor-
rected iPS cells were then directed to differentiate into hematopoietic progenitors
cells, which rescued the sickle-cell phenotype in affected mice upon transplantation.
Similar experiments involving transplantation of iPS derived dopaminergic neurons in
rats and hiPS derived cardiomyocytes in rodents helped rescue phenotypes associated
with Parkinsons disease and defects in cardiac contractile function respectively [65,66].
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Hence, hiPSCs offer a wide array of possibilities for disease modeling and generation
of patient-specific cell lines. They aid in modeling the disease phenotype in vitro
and help to identify fundamental differences within the cells of individual patients.
This is especially important in diseases like age-related macular degeneration, long
QT syndrome or spinal muscular atrophy where evolutionary differences limit disease
modeling using animals [67]. One of the earliest applications of this protocol was il-
lustrated in 2008 where iPS cell lines where derived in order to model several diseases
including Huntington’s disease, Parkinson’s disease and Down’s Syndrome [68, 69].
One of the best examples of the use of hiPSCs was demonstrated in an attempt to
model Spinal muscular atrophy [70]. Fibroblasts were derived from an affected pa-
tient and were induced to form iPS cells. These cells were then differentiated to form
motor neurons that illustrated the deficits in the disease phenotype when compared to
the wild type. Similar experiments performed on other diseases including LEOPARD
syndrome, Familial dysautonomia, Long QT syndrome and Gyrate atrophy further
illustrate the applicability of diseases to successfully recapitulate the disease pheno-
type [71–78]. The present use of this technology however is greatly limited to simple
monogenetic diseases and needs to be further developed to successfully mirror com-
plex diseases like Alzheimers which have a long latency period [79].
Owing to their innate ability to recapitulate human development in vitro, hiPSCs
have also been implicated in their role in drug development. However, a number of
steps need to be followed to successfully use iPSCs for drug development [80]. First,
reliable samples (fibroblasts or blood samples) need to be obtained from a patient
with the disease phenotype along with appropriate controls in accordance with the
established guidelines [81]. Second, high quality iPS cell lines need to be generated
and be characterized extensively. Third, the cell lines should possess the capability
to differentiate to the cell types affected in the disease and successfully recapitulate
the disease phenotype. Last, an effective and robust assay needs to be generated
for the disease phenotype with the capability of conversion into a large-scale assay
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for high-throughput screening of drugs in future. One of the first examples of this
technique was demonstrated in human embryonic stem cells where potentiaters of
glutamate receptors were identified [82].
Despite many advances to date, significant obstacles still remain before this potential
is realized due to the possibility of graft rejection and zoonosis resulting from the
use of animal products or other undefined components in the medium which need
to be addressed before effective cell replacement therapy can be warranted [84, 102].
Hence, a major goal of this field of research is the development of xeno-free differ-
entiated progeny cells derived from hPSCs which could then be successfully used for
translational research and regenerative medicine.
1.7 hiPSCs and Retinal development
Human pluripotent stem cells, including Human Embryonic Stem cells (hESCs) and
hiPSCs, provide a unique in vitro system to study human development. This is par-
ticularly useful to study early events in development, such as retinogenesis. Several
approaches have been used to model retinogenesis in vitro using hESCs: One of the
first experiments illustrating the use of hESCs was described in 2004 where hESCs
were directed to form RPE [85]. Later, in 2006, it was demonstrated that retinal
progenitor cells could be derived using hESCs using three factors namely IGF, Dkk-1
and Noggin [86]. It had been previously demonstrated that the use of Bone Morpho-
genetic Protein (BMP) and WNT inhibitors is necessary to direct cells to anterior
neural phenotype [87–90]. Hence, in 2009, another group of researchers derived retinal
cells from hESCs-specifically photoreceptors and RPE utilizing other factors in addi-
tion to Dkk-1 such as Lefty-A, Sonic hedgehog (SHH), retinoic acid, activin-A [91].
This study was a clear example of mirroring retinal development in humans where the
derivation of retinal cells was established in a step-wise manner wherein transcrip-
tion factors were used to indicate each stage of development. The use of hiPSCs to
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derive retinal cells was demonstrated in 2009 where Dkk-1 and Lefty-A were used to
direct hiPSCs to a retinal phenotype [92]. As an effort to identify retinal progenitor
cells from hiPSCs early in development, an efficient protocol was also developed in
2009 [93]. This protocol not only recapitulated the exact events of retinogenesis but
also presented an elegant and unique way to identify retinal progenitor cells as early
as twenty days of differentiation. This was also the first demonstration of derivation
retinal cells in culture in the absence of any exogenous signaling factors. Furthermore,
this study convincingly described the derivation of retinal ganglion cells, photorecep-
tors and RPE from retinal progenitor cells derived from hiPSCs with an efficiency of
almost 90%.
Figure 1.4. [93] Flowchart illustrating the protocol used for directed dif-
ferentiation of hiPSCs into retinal cells. Markers expressed at different
stages of development help model retinogenesis in vitro.
It has been previously established that hiPSCs can be directed to cells of an anterior
neural lineage in a manner that mimics normal neurogenesis [93, 117] (Figure 1.4).
Also, it has been demonstrated that the establishment of a retinal fate from an un-
specified stem cell source occurs via a step wise process through an anterior neural
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intermediate [91, 93, 105]. The first step in this process is the loss of pluripotency
associated markers as the cells progress along the path of differentiation. After ten
days of differentiation, a primitive anterior neuroepithelium is established, marked
by the coordinated and overlapping expression of the EFTFs [93]. The expression of
these EFTFs along with other anterior neural markers provides an anterior specificity
to the cells, while laying the groundwork for retinal specification. After 20 days of
differentiation, two morphologically distinct populations arise when the cells are in
suspension. One type of cell population has a light outer ring surrounding the spher-
ical cells while the other types do not possess the ring-like morphology [117]. These
populations express a different set of genes; the cells having the unique phenotype ex-
press retina associated genes whereas cells belonging to the other populations express
other anterior neural genes of the developing forebrain. The use of morphological
features to isolate neurospheres which are reminiscent of the optic vesicle helps in
enriching the number of retinal progenitor cells in a mixed population. These spheres
then develop into mature retinal cell types such as photoreceptors and ganglion cells
over 80 days of differentiation with almost 90% efficiency.
1.8 Aim of the study
hiPSCs have been demonstrated as a unique in vitro model with which to better un-
derstand human retinogenesis. Although researchers have been successful in deriving
retinal cells in culture, the pathways underlying the specification of a retinal pheno-
type have not been studied in depth. A number of transcription factors and bHLH
factors have been known to play an important role in vertebrate retinal development.
A close look into these factors suggests prominent roles played by the Eye Field Tran-
scription Factors (EFTFs). Previous studies in lower model systems like xenopus and
mouse indicate trends in the expression of these EFTFs as the eye develops from the
pimitive neuroectoderm [8,12–14]. For example, certain EFTFs maintain a high level
of expression after their onset, while others demonstrate more variable expression
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levels [12]. A similar trend is observed when hiPSCs are directed to differentiate into
retinal cells where some EFTFS are specifically retained in the retinal neurospheres
as opposed to the non-retinal neurospheres, thereby indicating a prominent role of
EFTFs in specifying a retinal phenotype [117]. This is interesting as the mechanisms
underlying the emergence of these discrete populations of cells in humans have not
been studied in depth. Characterization of the trends and roles of EFTFs will help
in identifying candidate EFTFs that govern the specification of a retinal fate. Also,
a deeper understanding of these mechanisms will help enrich the number of retinal
progenitor cells in culture, providing more retinal cells for translational purposes.
To summarize, the experiments described within this thesis seek to use hiPSCs as a
unique in vitro model with which transcriptional regulation of human retinogenesis
can be studied. Additionally, experiments were designed to determine the ability
of hiPSCs to be maintained and differentiated into a retinal phenotype under non-
xenogeneic conditions for future translational applications.
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2. TRANSCRIPTIONAL REGULATION OF RETINAL SPECIFICATION USING
hiPSCs AS A MODEL SYSTEM
2.1 Introduction
Development of the vertebrate eye is a complex process that is dependent upon the
activity of numerous transcription factors [14, 143]. Out of these factors, the EFTFs
have been known to play a crucial role in specifying the timing as well as the location
of the eye during its development [12,13]. These include a group of seven transcription
factors namely pax6, lhx2, six3, six6, nr2e1(tll), rax and tbx3(et). Previous studies
done in model systems like Xenopus and mouse have helped to shed light on the
highly dynamic and overlapping patterns of expression of these EFTFs [8,14,95,96].
However, the evolutionary differences between humans and other vertebrates slightly
limit the applicability of these studies to successfully understand human development.
Therefore, with the development of Human pluripotent stem cells (hPSCs), including
both human embryonic stem cells (hESCs) and human induced pluripotent stem cells
(hiPSCs), some of the disadvantages associated with traditional model systems such
as Xenopus or mouse can be overcome and hence, hPSCs serve as powerful in vitro
models for study of human development.
Human induced pluripotent stem cells (hiPSCs) were first established in 2007 by two
groups of leading researchers [53, 54]. Since then, variety of protocols have been de-
veloped to direct these cells to a retinal fate [92, 93, 117]. In the Meyer lab, hiPSCs
were directed to differentiate toward a retinal lineage using a targeted, stepwise dif-
ferentiation process that mimics human retinogenesis [93,116,117]. From a primitive
anterior neural population derived from hiPSCs, populations of retinal and forebrain
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progenitor cells could be readily identified within the first 20 days of differentiation.
However, the process by which a retinal fate is specified from a primitive anterior
neural progenitor cell remains largely elusive. Building upon our previous studies; we
sought to establish the role of key transcription factors during the establishment of a
retinal fate.
2.2 Methods
2.2.1 Thawing hiPSCs
The hiPS cell line IMR90-4 was chosen by the Meyer lab to study retinal development
in vitro. This cell line was chosen due to its ability to generate retinal cells and mirror
retinogenesis, as demonstrated previously. [93, 117]. The cells were obtained from
WiCell and were immediately thawed in a water bath at 37 ◦C upon delivery. They
were then transferred to a 15ml conical tube and spun at 800rpm for one minute on
a bench-top centrifuge for removal of DMSO (anti-freeze agent) from the medium.
The cells were then re-suspended in 2ml of TeSR medium and were plated on plates
coated with matrigel.
2.2.2 Passaging hiPSCs
hiPSCs were supplemented by the addition of 2ml of TeSR medium per well on a daily
basis. Upon reaching the desired confluency of 70-80%, good colonies were expanded
in a ratio of 1:6. Compact and homogenous colonies with a defined boundary were
archetypes of good colonies and were expanded further. Colonies in which individual
cells could be visualized were removed manually. hiPS clonies were lifted from the
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plate by enzymatic treatment with dispase followed by three washes with DMEM-
F12. They were then subjected to vigorous pipetting to disassociate the colonies into
smaller clusters and were plated on matrigel-coated plates. Passaging was repeated
when hiPSCs reached the desired confluency.
2.2.3 Freezing of hiPSCs
After passaging, cells were re-suspended in medium containing 70% TeSR medium,
20% Fetal Bovine Serum (FBS) and 10% DMSO. Each well accounted for one aliquot;
henceforth, six aliquots of one ml each were made from a single six-well plate. These
aliquots were stored in a cryovial at -80 ◦C temporarily, followed by transfer to liquid
nitrogen for long-term storage.
2.2.4 Differentiation of hiPSCs
Induction of iPSCs toward an anterior neuroectodermal fate was performed as previ-
ously described for hESCs and hiPS cells. Briefly, hiPSCs were enzymatically lifted
from 6 well plates using dispase (1mg/ml) with mechanical scraping and grown as
aggregates in suspension for 3-4 days to initiate differentiation as embryoid bodies
(EBs). The EBs were then switched to a chemically defined neural induction medium
(NIM), which consisted of DMEM/F12, N2 supplement, MEM non-essential amino
acids and 2mg/ml heparin. Two days later, EBs were allowed to attach with the
addition of laminin. Within a few days, columnar cells developed and formed neural
tube-like structures within a week. To allow for retinal differentiation, the medium for
the hiPSC-derived neuroepithelial rosettes was switched to a retinal differentiation
medium (RDM) consisting of DMEM/F12 (3:1) supplemented with B27 on day16
of differentiation. For neural retinal progenitors, rosettes were mechanically isolated
from adherent cultures upon change of medium with light trituration. Neurospheres
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possessing a light ring-like appearance around the periphery were separated using
a P20 pipette. These cells were then placed in suspension culture in non-adherent
culture dishes till 20 days of differentiation.
2.2.5 Q-PCR
Cells were removed from the plate with the use of a cell scraper and were collected in
0.5ml tubes. Samples were collected every two days, starting from Day0 (D0) until
Day20 (D20) and RNA was isolated from these cells using the RNAeasy kit (Qiagen)
and Picopure RNA isolation kit (Life Technologies). During this procedure, a 15
minute DNAase step was done in order to remove any contaminating DNA from the
RNA samples. Next, cDNA synthesis was done using iScript cDNA synthesis kit by
BioRad. Following cDNA synthesis, the samples were diluted in a ratio of 1:10 and
were further analyzed by Q-PCR. For 20µL Q-PCR reactions, 10µL of SYBR green,
4µL of water, 2µL of primers (300µM concentration) and 4µL of DNA were added.
Q-PCR was performed for 40 cycles via stages of initial heating (95 ◦C, 15 minutes),
denaturation (95 ◦C, 20seconds), annealing (60 ◦C, 30 seconds) and extension (72 ◦C,
1 minute) stages. Samples were run in triplicates with β-ACTIN as the endogenous
control and each experiment was repeated a minimum of three times.
2.2.6 Immunocytochemistry
Neurospheres or embryoid bodies were plated onto poly-ornithine/laminin coated cov-
erslips overnight to allow for attachment. These were then fixed with 4% paraformalde-
hyde at the required time point in order to examine the translation of the RNA tran-
scripts into mature protein. Following the fixing step, the coverslips were washed
three times with PBS followed by incubation with 0.2% triton-X for ten minutes.
Non-specific binding of the antibodies was prevented by incubating the cells with
10% donkey serum for an hour. This was followed by the addition of the primary
antibody in 5% donkey serum and 0.1% triton-X at the recommended dilution. Fol-
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lowing overnight incubation at 4 ◦C, cells were washed 3X PBS in order to remove
the primary antibody. After a brief incubation for 10 minutes in 10% Donkey serum,
Secondary antibody and DAPI were added at a dilution of 1:1000. This was followed
by 3X washes with PBS and mounting of the coverslips on slides using mounting
medium. Labeled cells were visualized with either Cy3-conjugated or Alexafluor488
secondary antibodies and nuclei were stained with DAPI. Images were obtained on a
Leica 5500 upright epifluorescence microscope.
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Table 2.1
List of antibodies used for Immunocytochemistry
Antibody Species Dilution
used
Source
ZO-1 Rabbit 1:100 Invitrogen
PAX6 Rabbit 1:100 Stemgent
BESTROPHIN mouse 1:100 Millipore
β-III TUBULIN mouse 1:1000 Covance
BRN3 goat 1:200 Santa Cruz Biotech.
CHX10 sheep 1:200 Exalpha Biol Inc.
EZRIN rabbit 1:100 Cell Signalling Tech.
ISLET-1 mouse 1:200 Exalpha Biol Inc.
LHX2 goat 1:1000 Santa Cruz Biotech.
NANOG goat 1:20 R&D Sys Inc.
OCT-4 rabbit 1:100 Stemgent
OTX2 goat 1:1000 R&D Sys Inc.
RAX rabbit 1:200 Millipore
RECOVERIN rabbit 1:1000 Millipore
SIX6 rabbit 1:200 Sigma-Aldrich
SOX1 goat 1:1000 R&D Sys Inc.
SSEA-4 mouse 1:100 Stemgent
TRA-1-60 mouse 1:100 Stemgent
TRA-1-81 mouse 1:100 Stemgent
ZO-1 rabbit 1:100 Invitrogen
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2.3 Results
2.3.1 Preliminary data
Previous studies from the Meyer lab have demonstrated the ability to derive retinal
cell types from hiPSCs following a method that closely recapitulates what is known
about human retinogenesis [93, 117]. However, these retinal cells arise in a mixed
population which includes other anterior neural cell types. As hiPSCs are directed
to differentiate into retinal cell types, two distinct populations arise within the first
twenty days of differentiation as the cells are grown in floating aggregates known as
neurospheres. These neurospheres can be identified based on their morphology and
manually separated into retinal and non-retinal groups. Those neurospheres with a
light outer ring around the periphery develop into retinal cells while cells lacking this
morphological feature develop into other anterior neural cells, most notably of the
forebrain [117].
Based on these previous results, experiments were designed to better understand the
emergence of these two distinct populations and decipher the signals that govern the
specification of retinal fate versus forebrain fate. Therefore, samples were collected for
the first twelve days of differentiation and were analyzed by RT-PCR. Initially, differ-
entiating cultures of hiPSCs were screened for their expression of neural transcription
factors and EFTFs (Figure 2.1). Based on these experiments, it was observed that
numerous transcription factors displayed similar trends in their expression patterns
where their expression began at day 4 of differentiation and was retained until at
least day 12 of differentiation. Of note was the observation that certain transcription
factors such as RAX exhibited varying trends in their expression patterns in the same
time-frame, where RAX expression seemed to peak by day 8 of differentiation and
was subsequently reduced at later timepoints. Based on this preliminary data, we
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decided to extend our time point to twenty days of differentiation and the data was
quantified using the technique of Q-PCR to get a deeper insight into the role of these
EFTFs in retinal development.
Figure 2.1. RT-PCR data illustrating the expression of EFTFs in hiPSCs
over 12 days of differentiation.
2.3.2 Loss of pluripotency
The acquisition of a more differentiated fate from hiPSCs requires that the cells lose
characteristics of pluripotency and acquire characteristics of advancing stages of de-
velopment. Initially, undifferentiated hiPSCs express pluripotency-associated factors
in a homogenous and uniform manner. This is illustrated by the techniques of Q-
PCR and ICC wherein the cells express markers like OCT4 and NANOG (Figure 2.2).
However, upon directing hiPSCs on the route of differentiation, they lose the expres-
sion of these genes overtime as demonstrated by immunocytochemistry results, which
depict the gradual loss of expression of these markers by day 8 of differentiation (Fig-
ure 2.2A,B).
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The ICC data was collected until day 8 of differentiation due to lack of a positive
signal after that time point while Q-PCR was performed over a timecourse of the
first twenty days of differentiation. Q-PCR confirms the earlier trend by establishing
the gradual loss of expression of OCT4 over twenty days of differentiation (Fig-
ure 2.2C). OCT4 expression was maximal at the initiation of differentiation (Day0),
with marked decrease in expression at day 2 and day 4. By day 8 of differentiation,
OCT4 expression is minimal and this lack of OCT4 expression is retained till day
18 of differentiation. Hence, the techniques of ICC and Q-PCR demonstrate the suc-
cessful of loss of pluripotency-associated genes upon differentiation of hiPSCs.
Figure 2.2. hiPSCs lose the expression of pluripotency-associated mark-
ers such as OCt4 and NANOG upon differentiation. ICC illustrates the
gradual loss of expression of OCT4 (A) and NANOG (B) over 8 days of
differentiation. Q-PCR data indicates loss of expression of OCT4 and
NANOG over twenty days of differentiation(C).
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2.3.3 Primitive anterior neural specification
As hiPSCs are directed to differentiate into cells of the retina, the earliest markers
that appear are analogous to the establishment of the anterior neural plate. The
expressions of genes such as PAX6 and OTX2 at this stage are indicative of the
emergence of the nascent anterior neural plate. PAX6 is a wide-ranging marker of
neural progenitor cells while expression of OTX2 is more confined to the forebrain-
midbrain region and their coordinated expression indicates the specification of the
primitive anterior neuroepithelium. The eye field is specified from this primitive neu-
roepithelium at later stages of development.
During the differentiation of hiPSCs to a retinal fate, the expression of these genes
occurs very early in development, with the expression of PAX6 beginnings at approx-
imately day 4 of differentiation (Figure 2.3A), while OTX2 expression is observed
in undifferentiated cells and is retained as these cells proceed along a neural lineage
(Figure 2.3B). As differentiation progresses, the expression of these markers increases
till twenty days of differentiation, as demonstrated by immunocytochemistry exper-
iments which depict these patterns of expression of these markers. Q-PCR further
recapitulates the trends seen in the expression patterns of PAX6 and OTX2 and their
role in establishing a primitive anterior neural fate is highlighted (Figure 2.3C,D).
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Figure 2.3. The acquisition of a primitive anterior-neural fate was illus-
trated by the expression of neural transcription factors like PAX6 and
OTX2 within 4 days of differentiation, with increasing expression lev-
els until 20 days of differentiation (A, B). The trends seen by ICC were
quantified by Q-PCR, which further highlights the expression patterns of
PAX6 and OTX2 over twenty days of differentiation (C, D).
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2.3.4 Definitive neural specification
As hiPSCs are directed on the route of differentiation, they mimic neurogenesis by
expressing markers specific to different stages of neurulation. The establishment of
the anterior neural plate is the first step of neurulation, indicated by the markers
PAX6 and OTX2. Next, the neural tube folds on itself to form the neural tube,
which is recapitulated in differentiating cultures of hiPSCs by the presence of neural
rosettes in culture beginning around Day 12 of differentiation. Cells of the rosettes
are positive for transcription factors like SOX1, PAX6 and OTX2, hence establish-
ing a definitive neural identity to these cells. The onset of expression of SOX1 has
been previously demonstrated to correlate with the definitive regional specification
of neural cells [94, 152] and thus, the data presented here helps to demonstrate the
combinatorial expression of transcription factors including SOX1, PAX6 and OTX2,
establishing a definitive neural identity to these cells (Figure 2.4).
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Figure 2.4. Expression of SOX1 over the first twenty days of differenti-
ation indicated the gradual acquisition of a neural fate (A, C) while ex-
pression patterns ofDLX5 (B) over the same time course helped identify
a forebrain-specific fate within the differentiating hiPSCs. These markers
were differentially expressed in the non-retinal spheres as compared to the
retinal spheres [117].
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Between the retinal and non-retinal populations of cells derived from this induction
protocol, it is likely that important transcriptional differences exist to specify a retinal
or forebrain fate. It was observed that the expressions of certain transcription factors
were restricted within only a subset of neurospheres, potentially underlying a mecha-
nism by which retinal and forebrain fates are established. Among these transcription
factors, SOX1 is often expressed in many neural progenitor cells, while DLX5 is more
restricted to forebrain regions. Importantly, the expression of these transcription fac-
tors is typically not observed in the retina [93]. Q-PCR indicates similar trends in
the patterns of expression of SOX1 and DLX5, where their expression starts around
day 8 of differentiation and is retained till day 20 of differentiation (Figure 2.4C, D).
Immunocytochemistry results further confirms the Q-PCR data wherein the onset of
the expression of SOX1 and DLX5 is seen at day 8 of differentiation (Figure 2.4A,
B). The expression of these factors increases with the progress of differentiation and
is retained until at least twenty days of differentiation.
2.3.5 Eye field transcription factors
As the neural plate fold on itself to form the neural tube, the optic grooves are formed
on each side develop into optic vesicles upon neurulation. Evagination of optic vesicle
towards the head ectoderm causes exchange of signals, leading to induction of the
retina and RPE [6]. A number of factors regulate the specification of the retina,
with the EFTFs playing a prominent role [14]. EFTFs include a set of transcription
factors namely PAX6, LHX2, SIX3, TBX3, NR2E1, SIX6 and RAX [12]. Q-PCR
highlights significant trends in the expression patterns of these factors in the differ-
entiating cultures of hiPSCs.
The expression patterns of PAX6, LHX2, SIX3, TBX3 and NR2E1 are highly similar,
with the onset first evident at approximately day 4 of differentiation and is retained
up to at least day 20 of differentiation. Q-PCR confirms the highly coordinated and
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overlapping patterns of expression of these factors (Figure 2.5B-E), whereas immuno-
cytochemistry results also reveals trends in the expression patterns of LHX2 similar
to what had been observed earlier for PAX6, with an onset of expression at day 4 of
differentiation and persistent expression until at least day 20 of differentiation (Fig-
ure 2.5A). The simultaneous and overlapping expression of these factors is indicative
of the complex signaling processes involved in the specification of the eye within the
first twenty days of differentiation.
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Figure 2.5. Eye field transcription factors (EFTFs) such as LHX2, TBX3,
NR2E1 and SIX3 displayed similar patterns of expression (A-E). The
onset of expression of these genes occurred after approximately 4 days of
differentiation and increased through day 20 (B-E). Immunocytochemistry
and Q-PCR indicated that the expression of many transcription factors
was maintained at high levels, although the expression of LHX2 began to
decrease as observed via immunocytochemistry at some later time points
(A,B).
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2.3.6 Key retinal specification genes
While many EFTFs were expressed in a ubiquitous fashion, efforts were undertaken
to indentify varying patterns of expression that could potentially account for the
adoption of a retinal fate. Transcription factors such as PAX6, LHX2, SIX3, NR2E1
and TBX3 had very similar patterns of expression, with an onset of expression at day
4 of differentiation followed by an increase of expression until day 20 of differentia-
tion (Figure 2.5). However, RAX and SIX6 were two transcription factors identified
that exhibited variations in their expression patterns, potentially indicating a more
prominent role in specifying a retinal phenotype.
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Figure 2.6. The expression of the eye field transcription factors RAX and
SIX6 varied in their expression patterns compared to the other EFTFs.
ICC demonstrated the expression patterns of RAX, which began its ex-
pression around day 4 of differentiation (A) and SIX6 (B), which began its
expression late, around day 14 of differentiation. RAX peaked early fol-
lowed by a gradual reduction, presumably becoming restricted to a subset
of retinal cells (C). The expression of SIX6 was not observed until after
the expression of other EFTFs (D), with an expression pattern found only
within a subset of neurospheres by 20 days of differentiation.
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Previous studies in the Meyer lab have indicated that RAX and SIX6 are two tran-
scription factors whose expression is restricted to the retinal cells at twenty of differen-
tiation and absent in non-retinal cells at this time point [117]. However, the dynamic
expression patterns of these transcription factors over time remained to be further
characterized. Immunocytochemistry results from our work indicated an early onset
of RAX expression beginning at day 4 of differentiation while SIX6 has a late, delayed
onset of expression, starting at day 14 of expression (Figure 2.6A,B). Interestingly,
Q-PCR indicates variable trends in the expression of these factors. RAX expression
increased until day 10 of differentiation followed by a sudden decrease in expression
at day 12 of differentiation (Figure 2.6C). The level of expression of RAX at day 12
is still higher than the expression levels at Day 0, indicating decrease in expression
as opposed to loss of RAX expression, potentially indicating that RAX expression is
retained in those cells committed to become retinal cells. After day 12, the expression
of RAX is retained at a constant level for twenty days of expression. Hence, the trends
for RAX based on the QPCR data seem to indicate the retention of RAX expression
exclusively in the cells which will adopt a retinal phenotype after day 12 of expression.
Interestingly, SIX6 peaks around day 12 of differentiation, about the time that RAX
expression levels drop (Figure 2.6D). Also, SIX6 expression is appeared to be exclu-
sive to the retinal cells by twenty days of differentiation. This data allows for the
possibility that the maintained expression of RAX ‘primes’ the cells to adopt a reti-
nal phenotype, with the subsequent expression of SIX6 committing these cells to a
retinal fate. Hence, this data indicates the applicability of RAX and SIX6 as candi-
date transcription factors playing significant roles in specifying a retinal fate from an
unspecified stem cell source.
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2.4 Discussion
The specification of the retina is a complex process, regulated by a variety of bHLH
factors, transcription factors and homeobox genes such as EFTFs [11, 12, 97]. Previ-
ously, animal models such as Xenopus and mouse have been used to study and model
human retinogenesis [8,140]. However, the evolutionary differences between lower ver-
tebrate models such as Xenopus and humans slightly limit the applicability of such
animal-based studies to effectively model human development [98,99]. The advent of
Human pluripotent stem cells (hPSCs), including both human embryonic stem cells
(hESCs) and human induced pluripotent stem cells (hiPSCs), help overcome some
of the disadvantages associated with traditional model systems such as Xenopus or
mouse and hence, serve as powerful in vitro models for human developmental studies
and genetic diseases.
A variety of genes, including EFTFs, have been known to play an important role in
the development of retina in lower vertebrates [14]. The roles of EFTFs have been
well characterized in Xenopus and mouse [8, 12] but their patterns of expression in
higher organisms, including humans, have been limited. The data presented here
is the first demonstration of the expression patterns of EFTFs in humans with the
use of hiPSCs as an in vitro model. This study highlights the highly dynamic and
overlapping patterns of expression of EFTFs in cultures of hiPSCs over twenty days
of development. EFTFs like LHX2, TBX3, SIX3, NR2E1 and PAX6 have similar
patterns of expression: they begin their expression around day 4 of differentiation
and are retained in hiPSC cultures till twenty days of differentiation (Figure 2.5).
However, two EFTFs, RAX and SIX6 demonstrate differences in their expression
patterns which indicate a more prominent role of these factors in specifying a retinal
fate (Figure 2.6). Based on this data, RAX and SIX6 were identified as candidate
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transcription factors involved in specifying a retinal fate from a primitive anterior
neuroectoderm population. Future studies involving gene overexpression or knock-
down of these candidate transcription factors will help discern the exact roles of these
factors in specification of a retinal fate.
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3. DERIVATION OF RETINAL CELLS FROM hiPSCs UNDER XENO-FREE
CONDITIONS
3.1 Introduction
Human induced pluripotent stem cells (hiPSCs) have been implicated to hold great
potential for regenerative medicine through the unique ability to generate patient spe-
cific cell lines, which account for fundamental differences within the cells of individual
patients and may potentially promote the development of a personalized treatment
profile for a wide spectrum of diseases [100, 101]. However, significant obstacles still
remain before this potential is realized due to the possibility of graft rejection and
zoonosis because of the use of animal products or other undefined components during
routine culture of these cells which needs to be addressed before effective cell replace-
ment therapy can be warranted [84,102]. Hence, a major goal of this field of research
is the development of xeno-free differentiated progeny derived from hiPSCs which
could then be successfully used for translational research and regenerative medicine.
Traditionally, human pluripotent stem cell (hPSCs) including human embryonic stem
cells(hESCs) and hiPSCs, have been grown on a layer of mitotically inactivated Mouse
Embryonic Fibroblasts (MEFs) in the presence of medium containing Fetal Bovine
Serum (FBS) or Knock Out-Serum Replacement (KOSR) allowing for the presence
of animal components under these growth conditions [86, 92, 103–106]. More recent
efforts have been made to eliminate the use of undefined growth conditions through
the use of chemically defined media [107–110]. However, such approaches often rely
upon defined animal proteins in the medium, as well as the growth of cells upon
a matrigel substrate [111]. More recent efforts have been focused on the growth of
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hPSCs under xeno-free conditions, along with the differentiation to limited cellular
lineages [112–115]. However, the successful growth and differentiation of hPSCs to a
retinal lineage has been largely unexplored. Thus, for translational purposes, a need
exists to enable the growth and differentiation of hPSCs in the absence of xenogeneic
materials.
We have previously demonstrated the derivation of a variety of retinal cells from
hPSCs including photoreceptors, retinal ganglion cells and RPE using a stepwise
differentiation protocol [93,116,117]. In the current study, we have adapted this pro-
cedure to allow for the successful growth and differentiation of hiPSCs to a retinal
phenotype in the absence of xenogeneic materials. Care was taken to ensure all an-
cillary components used in the process of differentiating hiPSCs were free of animal
origin to reinforce the applicability of hiPSCs to the field of translational medicine.
Here, we present a xeno-free technique for growth and differentiation of hiPSCs into
retinal cells that closely resembles previously established methods for derivation of
retinal cells, but is devoid of xenogeneic factors.
3.2 Methods
3.2.1 Maintenance of undifferentiated colonies
IMR90-4 hiPSCs (WiCell) were maintained in the undifferentiated state under three
different conditions; MEF, feeder-free (FF) and xeno-free (XF). The MEF system re-
quired the growth of hiPSCs on MEF, with the supplementation of iPS medium (20%
Knockout Serum, 0.1mM β-mercaptoethanol, 1mM L-glutamine, DMEM-F12(1:1),
MEM Non-Essential Amino Acids, 4ng/ml FGF2) on a daily basis. The feeder-free
system comprised of the growth of hiPSCs on matrigel and the use of mTESR1
medium (Stemcell Technologies) for maintenance of cells in an undifferentiated state.
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Lastly, the xeno-free system consisted of cells grown on Synthemax plates (Corn-
ing) with the addition of Nutristem medium (Stemgent). The use of MEF and
feeder-free system for the growth of hiPSCs has been reviewed extensively in lit-
erature [91–93,111,118,119], allowing for their role as controls for our experiments.
Cells were passaged approximately every four days, usually when the colonies cells
were 70-80% confluent. Colonies containing clearly visible differentiated cells were
manually removed before passaging. The remaining colonies were lifted off the plate
enzymatically by treatment with dispase (2mg/ml) followed by three washes with
DMEM-F12. Colonies were then broken up into smaller clusters by manual trituration
and were plated at a ratio of 1:6.
3.2.2 Differentiation of hiPSCs
Colonies of undifferentiated hiPSCs were directed to differentiate via the formation of
embryoid bodies (EBs) through treatment with dispase, as described previously [93].
Cells grown on the MEF system were immediately transferred to Neural Induction
Medium (NIM; DMEM-F12 (1:1), 1%N2 supplement, MEM Non-Essential Amino
Acids, 2µg/ml Heparin) whereas cells grown under feeder-free and xeno-free condi-
tions were slowly transitioned into NIM by transferring the EBs to a 3:1 ratio of
mTESR1/Nutristem: NIM on day 0, 1:1 on day 1, 1:3 on day 2 followed by transfer
to complete NIM at day 3 of differentiation.
At day 7 of differentiation, the cells grown on MEF and feeder-free system were plated
on 6 well plates coated with laminin (20µg/ml). To maintain a non-xenogeneic en-
vironment for xeno-free cultures, laminin coating was omitted and Synthemax plates
were used. Cells acquired advancing morphological features particular to neural
rosettes over 17 days of differentiation, followed by their transfer to Retinal Dif-
ferentiation Medium (RDM; DMEM-F12 (3:1), 2% B27, non-xenogenic B27 was used
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for XF system). Retinal neurospheres identified by a bright ring appearance around
the periphery were manually picked as previously established (Meyer et al., 2009).
Neurospheres were fed every 3-4 days and were maintained in suspension upto 60
days of differentiation. For RPE differentiation, cells were kept adherent at day 17 of
differentiation and were fed with RDM every 3-4 days until approximately 60 days of
differentiation.
3.2.3 Immunocytochemisty
Samples were collected at specified timepoints of differentiation and were plated
onto coverslips coated with poly-ornithine/laminin (20µg/ml), fixed with 4% para-
formaldehyde for 30 minutes followed by three washes with PBS for five minutes
each. The cells were permeabilized by treating them with 0.2% trypsin for ten min-
utes followed by blocking it for an hour with 10% donkey serum. Primary antibody
was added at the recommended dilution in 0.1% triton-X and 5% donkey serum and
incubated overnight at 4 ◦C. The next day, primary antibody was removed and cells
were washed 3X with PBS, followed by blocking with 10% donkey serum for ten min-
utes. The secondary antibody was diluted along with DAPI in 0.1% triton-X and 5%
donkey serum for an hour. Samples were then washed with PBS and mounted and
applied on slides using mounting medium.
In order to perform ICC on RPE, pigmented patches of cells were micro-dissected
manually and re-plated on Poly-orinithine/laminin coated coverslips. RPE cells were
supplemented with RDM containing FGF2 (20ng/ml), EGF (20ng/ml) and Heparin
(2µg/ml) for a week. Mitogens were then removed for two weeks and cells were stained
as described above.
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3.2.4 RT-PCR
Cells were collected at specified time points of differentiation and RNA was extracted
using PicoPure RNA Isolation Kit (Applied Biosystems). cDNA was made using
the iScript cDNA Synthesis Kit (Bio-Rad) or SuperScript III First-Strand Synthesis
System (Invitrogen). cDNA was used for RT-PCR using GoTaq qPCR Master Mix
(Promega). PCR was performed for 30 cycles followed by analysis of PCR products
on 2% agarose gels.
3.3 Results
3.3.1 Examining features of pluripotency under different conditions
The ability to effectively expand hiPSCs and maintain pluripotency is essential for
future applications. Thus, experiments were designed to analyze pluripotency char-
acteristics in hiPSCs cultures under the three conditions. After a minimum of five
passages in either MEF, feeder-free or xeno-free systems, colonies of hiPSCs exhib-
ited a uniform appearance without marked differences in the morphologies of the
colonies under the different culture conditions (Figure 3.1A). Under all three con-
ditions, immunocytochemistry results confirmed the expression of key pluripotency
associated factors in colonies of hiPSCs including OCT4, SOX2, NANOG, SSEA-
4, TRA-1-60, and TRA-1-81 (Figure 3.1B-G). Maintenance of the pluripotent state
was further confirmed through RT-PCR analysis, where key pluripotency genes were
found to be expressed under all conditions (Figure 3.1H). In addition to the expres-
sion of characteristic pluripotency genes, colonies of hiPSCs grown under each culture
condition also tested negative for the expression of differentiation markers including
α-FETOPROTEIN, PAX6 and BRACHYURY, further confirming their undifferen-
tiated state.
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Figure 3.1. Colonies grown under xeno-free, feeder-free and MEF system
of development exhibited similar morphological features when viewed un-
der bright field microscope (A). Uniform and homogenous expression of
pluripotency-associated factors like OCT-4, NANOG and SOX2 was ob-
served in the undifferentiated colonies, irrespective of the system they were
grown in (B-D). Similar expression of cell surface markers like SSEA-4,
TRA-1-61 and TRA-1-81 in the xeno-free cells when compared to tradi-
tional systems further confirm the pluripotency characteristics of these
cells (E-G). RT-PCR recapitulates the trends observed in ICC and con-
firmed the presence of the pluripotency-associated transcription factors
such OCT4, NANOG, SOX2, LIN28 and KLF4 and the absence of fac-
tors associated with differentiation like PAX6 (H).
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3.3.2 Specification of neural and retinal progenitor cells
Prior to the specification of mature retinal cells types, hiPSCs must be prompted to
differentiate through the major stages of retinal development including those stages
analogous to primitive eye field, optic vesicle and optic cup stages. Following modi-
fications to previously established protocols, hiPS cells initially acquired features of
primitive anterior neuroepithelium, including the eye field. Immunocytochemistry
and RT-PCR experiments illustrated the expression of transcription factors SOX1,
SOX2, PAX6 and OTX2 (Figure 3.2A-D), which were indicative of the acquisition
of an anterior neural phenotype. Importantly, inappropriate regional and temporal
gene expression was generally not observed within these cells, confirmed by the lack of
expression of markers associated with other germ layers and posterior markers of the
midbrain and hindbrain (HOXB4, ENI ; Figure 3.2G). The establishment of anterior
neural identity was also indicated by the emergence of the eye field stage, character-
ized by the expression of EFTFs [12] PAX6, RAX, SIX3, SIX6, LHX2 and NR2E1
(Figure 3.2G). Immunocytochemistry and RT-PCR experiments demonstrated co-
ordinated and overlapping expression of EFTFs in differentiating iPS cell colonies.
Moreover, the expression patterns of all transcription factors at this stage were sim-
ilar under all three conditions tested, illustrating the potential to derive retinal cell
types under non-xenogeneic conditions (Figure 3.2G).
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Figure 3.2. Following modifications of established neuroretinal induction
protocols, hiPS cells acquired features of the primitive anterior neuroep-
ithelium, including the eye field. Expression of SOX1, SOX2, PAX6 and
OTX2 confers a broad neural identity to these cells (A-D). Expressions of
numerous genes/proteins associated with the eye field stage such as LHX2
and SIX6 were observed within these cells after10 days of differentiation
(E, F). RT-PCR highlights the expression of all the transcription factors
associated at this stage of development. Importantly, inappropriate re-
gional and temporal gene expression was generally not observed within
these cells (G).
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Following the acquisition of a primitive eye-field like phenotype, hiPSCs must be di-
rected to differentiate towards subsequent stages of retinal development, including
those analogous to the optic vesicle and optic cup. We have previously demon-
strated the ability to identify and isolate two morphologically distinct populations
of cells in cultures of differentiating hiPSCs within the first twenty days of dif-
ferentiation with characteristics analogous to retinal and forebrain progenitor cells
[93, 117]. Neurospheres possessing a bright ring around the periphery were isolated
via bright field microscopy and expressed a full complement of retinal progenitor cell-
associated transcription factors such as CHX10 (Figure 3.3A,B), MITF and TBX2
(Figure 3.3F). Immunocytochemistry and RT-PCR experiments demonstrated the
expression of these transcription factors in xeno-free, feeder free and MEF conditions
(Figure 3.3A-F). The expression of some anterior retinal transcriptions factors such
as PAX6, LHX2, SIX6 (Figure 3.3C-E) and RAX (Figure 3.3F) were also maintained
in these spheres. The absence of mature retinal markers such as CRX and BRN3,
along with expression of CHX10 was suggestive of a retinal progenitor cell population
(Figure 3.3F). The consistency of expression of these transcription factors across all
three systems further illustrates the applicability of this differentiation protocol to
different systems (Figure 3.3F).
49
Figure 3.3. Under varying growth conditions, retinal progenitor spheres
can be isolated via brightfield microscopy. The retinal spheres were iden-
tified by a light outer ring around the periphery, a morphological feature
absent in non-retinal spheres (A). The retinal cells stained positive for
CHX10, a marker for retinal progenitor cells (B). The cells grown on
all three systems retained the expression of EFTFs like PAX6, LHX2 and
SIX6 (C). RT-PCR data confirms ICC trends and indicates similar expres-
sion levels of cells grown in a non-xenogenic environment when compared
to the cells grown using traditional systems. More mature markers like
CRX and BRN3 are absent at this stage (D).
As opposed to those neurospheres that gave rise to retinal progenitor cells, the
other neurospheres were previously demonstrated to be composed of forebrain pro-
genitor cells. These neurospheres contained neural progenitors of an anterior iden-
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tity (SOX1/PAX6/OTX2 -positive) as well as βIII-TUBULIN positive neurons (Fig-
ure 3.4A-D). As demonstrated by RT-PCR analysis, these neurospheres expressed
a full set of anterior neural transcription factors such as FOXG1, DLX1 and GSX2
(Figure 3.4E). These results demonstrates that the ability to enrich for retinal progen-
itor cells apart from other neural cell types is maintained under xeno-free conditions,
as previously established for traditional systems.
Figure 3.4. Non-retinal neurospheres express markers indicative of ante-
rior neural phenotype like PAX6, OTX2 and SOX1 at 25 days of differ-
entiation (A-C). The loss of OTX2 expression in some cells is confirmed
by the presence of more mature neuronal markers like βIII-tubulin neu-
rons, indicated by white arrows (C,D). RT-PCR analysis demonstrates
that these cells express a full complement of anterior neural transcription
factors (E).
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3.3.3 Differentiation of mature retinal cell types
For future translational applications, it will be necessary to derive more retinal cells
under non-xenogeneic conditions, including cells of both RPE and neural retina. In
the current study, hiPSCs could be directed to become RPE under xeno-free condi-
tions, similar to previous documentation in the MEF system. Pigmented, hexagonal
RPE-like cells were first apparent approximately one month following the start of
differentiation and increased over next few weeks (Figure 3.5A). Immunocytochem-
istry at 50 days of differentiation revealed the expression of RPE-associated tight
junction proteins such as ZO-1 as well as RPE associated transcription factor OTX2
(Figure 3.5B). RPE from both xeno-free and traditional cultures expressed a full com-
plement of RPE-associated genes such as RPE65, PEDF, ZO-1, MITF and BEST1
which were confirmed by RT-PCR (Figure 3.5C).
Figure 3.5. Bright field images confirm the presence of pigmented, hexag-
onal RPE-like cells. These were first apparent approximately one month
following the start of differentiation and increased over the next few weeks
(A). RPE retained the expression of OTX2 and stained positive for ZO-1,
a tight-junction protein associated primarily with epithelial cells (B). RT-
PCR from xeno-free and traditional cultures expressed a full complement
of RPE-associated genes (C).
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Beyond the ability to derive RPE cells, it will also likely be necessary to derive cells
of the neural retina under non-xenogenic conditions, including photoreceptors and
retinal ganglion cells. In the current study, we observed cells that had acquired
morphologies of primitive photoreceptor-like cells in vitro, after 50 days of differ-
entiation (Figure 3.6A). Cells expressed genes associated with varied neural retinal
phenotypes, with numerous cells expressing the photoreceptor precursor-specific tran-
scription factor CRX as well as RECOVERIN, indicative of a cone-photoreceptor fate
(Figure 3.6B). Additionally, other cells expressed BRN3, indicating the existence of
retinal ganglion cells in those cultures (Figure 3.6C). RT-PCR demonstrates the ac-
quisition of advancing features of retinal cells over 50 days of differentiation in a
xeno-free environment while mirroring the developmental process as previously doc-
umented in traditional systems.
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Figure 3.6. After 50 days of differentiation, cells acquired morphologies of
primitive photoreceptor-like cells in vitro, including a unipolar appearance
with one short process, as indicated by the arrows (A). Cells expressed
genes associated with varied neural retinal phenotypes, with numerous
cells expressing the photoreceptor precursor-specific transcription factor
CRX and RECOVERIN (B). Cells also express markers such as BRN3,
which are specific to retinal ganglion cells (C). RT-PCR indicates the ex-
pression of genes specific to different retinal subtypes such as CRX, which
is specific to photoreceptors (D). Due to acquisition of mature markers,
the retinal progenitor marker CHX10 is no longer expressed.
3.4 Discussion
The data presented here demonstrates the ability to derive retinal cell types from
hiPSCs via a differentiation protocol that excludes the presence of xenogeneic com-
ponents. We establish the feasibility to generate retinal cell types, including RPE,
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photoreceptors and retinal ganglion cells, from hiPSCs in a xeno-free manner with
minimal variability as compared to those cells derived by traditional methods of dif-
ferentiation. Such ability will likely be of great importance as hiPSC research is
developed for more translational purposes.
Several reports have focused upon the ability to derive retinal cell types from hiP-
SCs. However, most of these studies have relied upon xenogeneic culture systems
utilizing media containing animal products and/or mouse feeder cells to support
the growth of hiPSCs [104, 120–123]. The ability to derive retinal cells from hiP-
SCs under non-xenogeneic conditions could have potentially profound implications
for future approaches to the treatment of retinal degenerative disorders, includ-
ing age-related macular degeneration and glaucoma. More recently, a few reports
have focused on the ability to derive RPE cells in a less xenogeneic culture environ-
ment [85,119,121,124–126]. Such studies have successfully generated RPE cells, but
these systems have remained somewhat xenogeneic, in that, the use of FBS in the
medium raises possible cases of zoonosis [124]. Furthermore, studies to date have
excluded the ability to derive cells of the neural retinal including photoreceptors and
retinal ganglion cells [127].
To build upon previous studies and establish a truly non-xenogeneic system with
which to derive retinal cells from hiPSCs, we sought to maintain a xeno-free environ-
ment in our system in a two fold manner: Firstly, a defined, feeder-free alternative
for the growth of hiPSCs was developed through the use of synthetically-coated cul-
ture plates. Secondly, media devoid of xenogeneic components was used to ensure the
maintenance of a xeno-free environment through the course of the experiments, includ-
ing both expansion of hiPSCs as well as their differentiation to a more mature retinal
lineage. The ability to derive retinal phenotypes under non-xenogeneic conditions
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also has important implications for the development of stem cell-based approaches
to a variety of disorders, as many groups have demonstrated the ability to derive a
variety of neural cell types following similar differentiation paradigms [92,128].
The results presented in this study offer numerous advantages over previously de-
scribed approaches to derive retinal cells from hiPSCs [92, 106]. First, the non-
xenogeneic culture conditions established within this manuscript are completely chem-
ically defined, whereas previous studies often relied upon the use of serum or knockout
serum-containing medium at some stage of the differentiation process [124,129]. Ad-
ditionally, beyond the use of commercially available media supplements, this method
does not require the use of additional exogenous growth factors which may compli-
cate efforts to establish a non-xenogeneic culture system. Furthermore, as previously
demonstrated under traditional culture systems [117], we establish the ability to iden-
tify and enrich for retinal progenitor cell populations based upon morphological char-
acteristics, and now demonstrate this capability under non-xenogeneic conditions.
Such an ability to derive essentially pure populations of retinal progenitor cells under
non-xenogeneic culture conditions will likely be essential as translational applications
for hiPSCs are developed.
The results presented in this study establish the proof-of-principle that hiPSCs can be
specified to differentiate into mature neural cell types such as retinal neurons under
non-xenogeneic conditions. Such results are likely to have important implications as
new stem cell-based approaches are developed for the treatment of human disease.
This is of particular importance as the first clinical trials for human embryonic stem
cell-based products are underway for the potential treatment of age-related macular
degeneration [130]. Before cells grown under non-xenogeneic conditions can be uti-
lized in therapeutic applications, other precautions will likely be necessary. First, if
existing cell lines are utilized, it may be necessary to demonstrate that xenogeneic
material has not been retained by these hiPSCs. Alternatively, it may be advanta-
56
geous to derive new lines of hiPSCS under non-xenogeneic conditions, as described
previously for hESCs [131]. Additionally, routine culturing of these cells in a research
lab does not afford the same level of protection for a patient as those cells grown under
Good Manufacturing Practices (GMP). Before the translation of this research to ther-
apeutic applications, it will likely be advantageous to expand the results presented
here to include the differentiation of these cells under GMP-compliant environmental
conditions.
In summary, the results of this manuscript demonstrate the ability to differentiate
hiPSCs into a variety of retinal cell types under non-xenogeneic culture conditions.
This study represents the first demonstration of non-xenogeneic differentiation of
hiPSCs into neural retinal cell types such as photoreceptors and retinal ganglion cells,
which is likely to have important implications for the treatment of diseases such as age-
related macular degeneration and glaucoma. Of importance, no marked differences
in the maintenance and differentiation of hiPSCs into retinal cells were observed
between each of the three culture conditions. The results of this study also highlight
the applicability of non-xenogeneic growth and differentiation of hiPSCs to other
systems for translational applications. While additional studies are still necessary
before widespread application of hiPSCs for translational applications, the current
study serves to establish the feasibility of non-xenogeneic growth and differentiation
of hiPSCs for applications related to retinal development and disease.
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4. DISCUSSION
Human induced pluripotent stem cells (hiPSCs) are capable of differentiating into
any cell type of the body. Hence, they possess the ability to be directed to generate
a specific subset of cells, including nerve cells, muscle cells or blood cells. Due to this
ability, hiPSCs have been demonstrated to serve as an important tool for studying
human development, particularly, the development of neural structures such as the
retina. The ease of accessibility of the retina, as well as its highly organized structure
and a thorough understanding of the neural circuits supports the use of retina as the
popular system for hiPSCs mediated cell replacement.
Some of the earliest experiments to derive retinal cells from human stem cell popula-
tions were performed utilizing hESCs [86, 91, 93, 119, 132]. In order to model retino-
genesis in vitro, one of the first steps is to direct hPSCs to an anterior phenotype.
This has traditionally been accomplished through the use of inhibitors to block BMP
and WNT pathways to direct the cells to an anterior-neural fate [86]. However, these
compounds are expensive and often require cellular exposure during precise windows
of development. Additionally, it is necessary to ensure that in vitro development of
retinal cell types mirrors what is known about retinogenesis in vivo. For example, in
humans, rod photoreceptors are among the last cell types of the retina to develop,
as they are generated within first 100-120 days of development. However, some dif-
ferentiation protocols demonstrate the appearance of photoreceptor markers within
the first 30 days of differentiation [86]. Hence, although a variety of protocols are
efficient, they fail to successfully recapitulate retinal development.
Hence, efforts have been made to devise a differentiation protocol that mirrors human
retinogenesis. Based on these, a group in Japan derived retinal cells from hESCs us-
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ing a different set of inhibitors [91]. Initially, they used small molecule inhibitors to
direct the cells to an anterior neural fate. Later, the cells were induced to form pho-
toreceptors using retinoic acid and taurine. However, these cells arose within highly
mixed populations of cells and required culturing periods of up to 180 days to achieve
a photoreceptor fate.
Thus, a need existed to develop a protocol that allowed for the prospective isola-
tion of retinal progenitor cells and more closely mirrored the events known to occur
during normal human retinogenesis. Hence, the Meyer lab developed a protocol to
successfully direct pluripotent stem cells to a retinal fate, which takes in to account
the limitations of earlier protocols while presenting an efficient method to derive reti-
nal cells. One of the important issues emphasized by this protocol is the importance
of choosing the right cell line. It was established that different cell lines respond
differently to different growth factors and vary in their capability to adopt a neural
fate [93]. For example, some cell lines block BMP and WNT signaling on their own
while others did not demonstrate this ability [117]. Hence, based on this study, we
initially chose the hiPSC line IMR90-4 for our developmental studies.
The cell line IMR90-4 has been used by several labs previously to generate neurons
in a culture dish [21,117,133]. Since neurogenesis occurs before retinal specification,
these cells possess the capability to be directed towards a retinal fate. One of the
unique advantages of this cell line is that it blocks BMP and WNT signaling with-
out the addition of external inhibitors like Noggin and Dkk-1 [117]. Also, it has
been demonstrated that these cells adopt an anterior neural phenotype as their de-
fault neural phenotype. Hence, upon spontaneous differentiation, these cells express
PAX6, a broad neural marker, as well as many other markers of an anterior neural
fate including OTX2 and BF-1, hence acquiring an anterior-neural phenotype [21].
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The cells were directed to become cells of the retina in a manner that recapitu-
lates normal human retinogenesis [93, 117]. In order to study development in vitro,
transcription factors unique to each developmental stage were analyzed (Figure 1.4).
Hence, using this approach, cells at each stage of differentiation could be identified on
the basis of the markers expressed. Not only does this protocol faithfully document
retinogenesis, it does so without the use of any exogenous growth factors or inhibitors.
At each stage of development, the colonies exhibit morphological features reminiscent
of stages of human development (Figure 4.1). For example, neural rosettes observed
in cultures from Day 12-Day 16 of differentiation were reminiscent of closure of the
neural tube during neurogenesis in vivo [105,135].
Figure 4.1. Neurogenesis in humans (top) is recapitulated by hiPSCs in
vitro (bottom). Image modified from [93,138].
Previous studies have emphasized the use of growth factors to drive cells to a reti-
nal fate [86, 91]. In order to identify retinal cells in cultures, the cells are screened
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for transcription factors such as CHX10, which is an indicator of retinal progenitor
cells and later factors including BRN-3 and CRX, specific to retinal ganglion cells
and photoreceptors, respectively [139]. However, most techniques used to evaluate
the presence of transcription factors require that the cells have been already fixed or
lysed. Hence, an efficient way of identifying retinal progenitors in live cultures was
developed in the Meyer lab.
After twenty days of differentiation, cells were transferred to a suspension culture
where they rounded up and organized themselves into three-dimensional spheres [93,
117]. Upon observation under a bright field microscope, two distinct populations of
cells with different morphological features could be seen. Some spheres exhibited a
light donut-shaped ring on the periphery while other spheres did not. Interestingly,
the cells with the light ring around the periphery were reminiscent of the optic vesicle
stage of human development in both their organization as well as their pattern of
gene expression. The ability of these spheres to give rise to the optic cup structure
which later develops into a stratified retina has also been recently demonstrated using
mouse embryonic stem cells [136]. Similar studies involving blood derived human iPS
cells (TiPS-5 cell line) have demonstrated positive staining for retinal ganglion cells
and photoreceptors in these retinal spheres at day 80 of differentiation [137].
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Figure 4.2. Two morphologically distinct populations arise from a mixed
population of cells at day 20 of differentiation (A). Cells possessing a bright
outer ring were classified as vesicular spheres and expressed markers spe-
cific to retinal progenitor cells such as CHX10 (B,E). Non-vesicular spheres
lack the bright-outer ring and therefore lack the expression of CHX10 and
are positive for ISLET-1 instead (C,F,I). Different set of transcription fac-
tors are expressed by vesicular and non-vesicular neurospheres (J). Image
modified from [117].
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Upon analyzing the populations further, the spheres not only exhibited morpholog-
ical differences but also expressed a different set of transcription factors. Cells with
unique morphological features expressed CHX10, a marker for retinal progenitor cells
(Figure 4.2) They also expressed other transcription factors including LHX2, RAX
and SIX6 which were unique to this subset of cells. Also, the spheres void of the
light outer ring expressed anterior neural, yet non-retinal markers including ISLET-
1, SOX1 and DLX5. Hence, spheres with the light outer ring were categorized as
retinal spheres while other spheres were called non-retinal spheres. However, the
mechanisms underlying the emergence of these two populations have not been ex-
plored in detail. Hence, we decided to investigate the emergence of these populations
in culture by studying retinal development using hiPSCs as a model system.
Retinal development is a complex interplay of a variety of signaling molecules such as
BMP, FGF and WNT proteins, as well as the contributions of critical transcription
factors [140]. Certain transcription factors have previously been demonstrated to play
a more prominent role in retinal specification [141, 142]. Some of these factors have
been very well characterized in lower organisms like Xenopus and are referred to as
the EFTFs [12]. Interestingly, some of these EFTFs are initially expressed as early as
6 days of differentiation in hiPSC cultures and retained until 20 days of differentiation
in the retinal spheres exclusively, a time point at which definitive retinal progenitor
cell markers are expressed (Figure 4.2). Hence, we decided to further investigate ex-
pression patterns of EFTFs in hiPSC cultures.
The patterns of expression of EFTFs have been highly characterized in lower organ-
isms such as Xenopus [12–14, 143]. However, their patterns of expression in retina
and their role in specifying a retinal fate remain largely elusive in higher organisms,
including humans. Hence, we decided to characterize their patterns of expression in
hiPSCs to highlight their roles in retinal development.
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hiPSCs were accessed for their loss of pluripotency-associated genes in a gradual man-
ner to demonstrate the lack of any abnormalities in terms of differentiation of hiPSCs
(Figure 2.2A-C). Next, hiPSCs were studied for the expression of genes indicative
of establishment of the anterior neuroectodermal plate. Using animal models, it has
been established that Pax6 helps to determine the neuroectoderm in vertebrate de-
velopment [21, 144, 145]. Also, Pax6 plays an important role in eye development,
particularly lens formation and specification of retinal cell types [146–148]. Hence,
the expression of PAX6 beginning in hiPSCs at day 6 of differentiation is indicative
of the establishment of a primitive anterior neuroectodermal fate (Figure 2.3A,C).
Also, it has been established that Otx2 plays an essential role in the specification of
the anterior neuroectoderm and is also retained throughout the optic vesicle stage
and in the RPE of vertebrates [149, 150]. The expression of OTX2 in our cultures
highlights a similar trend in human development (Figure 2.3B,D). Interestingly, the
expression of OTX2 is observed as early as the undifferentiated state of hiPSCs, po-
tentially elucidating a mechanism for the ‘default’ acquisition of an anterior neural
phenotype within these cells.(Figure 2.3B).
Following the establishment of a neural fate, the next step of neurogenesis is the
folding of the neural plate to form the neural tube. This is accompanied by the
expression of definitive neural markers like SOX1 and DLX5 (Figure 2.4A-C). Ex-
periments conducted in Xenopus show that Sox1 expression directly correlates with
the establishment of the neural ectoderm [151]. Experiments conducted in human
embryonic kidney cells indicate similar functions of SOX1 [152], which is further con-
firmed by our data (Figure 2.4A,C), indicating that SOX1 promotes induction of
neurogenesis in differentiating cultures of hiPSCs. The colonies form neural rosettes
which express SOX1 in a homogenous manner (Figure 2.4A).
The expression of EFTFs was investigated to determine their role in specifying a
retinal phenotype in differentiating cultures of hiPSCs (Figure 2.5A-E). EFTFs have
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been investigated in detail in lower organisms like Drosophila and Xenopus [12,14,15].
However, their role in the development of the human eye, specifically the retina, has
not been characterized in detail. Studies of expression patterns of EFTFs indicates a
uniform and spontaneous activation of transcription of genes including PAX6, LHX2,
NR2E1, TBX3 and SIX3, which begin their expression around Day 4 of differen-
tiation. This is particularly interesting as experiments performed in Xenopus docu-
mented the expression of nr2e1 in later stages of development [12]. However, our data
indicates that NR2E1 begins its expression earlier, at day 4 of differentiation, along
with the onset of expression of many other EFTFs including LHX2, SIX3, PAX6 and
TBX3 (Figure 2.5A-E). This difference between Xenopus and humans may under-
score an important advantage of the use of hiPSCs over systems such as Xenopus.
Given that the developmental process is considerably shorter in lower organisms, and
that the expression patterns of these factors are highly similar and overlapping, it
may not possible to discern the role of one factor in establishing retinal fate versus
an anterior neural fate in this condensed timeline.
An interesting trend was seen in the expression patterns of other critical EFTFs
including RAX and SIX6 (Figure 2.6A-D). The function of Rax and its role in reti-
nal development has been studied extensively in vertebrate systems such as mice
[153, 155]. Rax is known to be important role in the formation of retinal progenitor
cells and the regulation of eye development in mice [153, 154]. However, the role of
RAX in human retinogenesis has not been studied extensively, often due to a lack
of suitable experimental material. Our data is not only the first in vitro cellular
model documenting the patterns and time course of RAX expression in humans but
also highlights the role of RAX in specifying a retinal fate (Figure 2.6A,C). RAX
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has an interesting pattern of expression where it begins its expression at day 4 of
differentiation and increases its expression until day 10 of differentiation after which
there is a sudden decrease, presumably becoming restricted to those cells that have
been committed to a retinal progenitor cell fate (Figure 2.6C). This trend has been
recently documented in the developing rat retina where densitometry quantification
experiments indicate similar patterns of expression for Rax [156].
Since RAX is retained in the hiPSCs-derived retinal cells at twenty days of differentia-
tion (Figure 3.3), the role of RAX in human retinal progenitor cells can be speculated
upon. Experiments in Xenopus suggest that rax might play a role in controlling the
proliferation of retinal progenitors as well as maintaining the progenitor cell popu-
lation in a multipotent stage [157]. Studies have also shown Rax to be important
in photoreceptor-cell fate specification at later stages of development [158]. Future
studies will have to done to evaluate the role of RAX in human photoreceptor de-
velopment. Nevertheless, based on previous literature and our data (Figure 2.6A,C),
RAX stands out as an important candidate transcription factor in specifying a retinal
fate.
SIX6 is another EFTF whose expression pattern makes it worthy of being considered
as a candidate transcription factor for retinal development. The expression of six6
has been well studied in Xenopus where overexpression of six6 has been shown to
lead to the formation of giant eyes with an accompanying expansion of retinal ter-
ritory [24, 28]. The expression pattern of SIX6 in hiPSCs was similar to what has
been documented previously in lower vertebrate models [12] where the expression of
SIX6 began later in development, around day 12 of differentiation (Figure 2.6B,D).
After that time, SIX6 expression was maintained at high levels in the retinal spheres
exclusively. Also, previously documented microarray data depicts a 40 fold increase
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of SIX6 in the retinal spheres when compared to the non-retinal spheres in culture,
thereby validating our data further [117]. Hence, our data emphasizes that SIX6
plays an essential role in retinal development.
An interesting feature about the expression pattern of SIX6 is that it peaked at the
same time that RAX expression decreased in these cells, at approximately day 10-
day12 of differentiation (Figure 2.6C,D). This is interesting as the expression patterns
of RAX and SIX6 in humans have not been documented previously. Recently, a study
speculated the role of Six6 as a repressor of non-retinal genes in Drosophila [159].
Also, Six3 and Six6 have been known to interact with repressors like groucho to
modulate eye development in Drosophila [160]. In vertebrate systems like medaka
fish, Six6 seems to play an important role for correct differentiation of amacrine cells
and photoreceptors of the retina [161]. In our hiPSC-based system, the patterns of
expression of RAX and SIX6 indicate a potential relationship in which RAX may
‘prime’ the cells for the acquisition of a retinal fate whereas the expression of SIX6
may function to commit the cells to a retinal fate.
In all, studies related to the transcriptional regulation of human retinal development
have been limited. With the advent of hiPSCs, we have been able to investigate the
roles of these factors in retinogenesis. Our data indicates the possible roles of RAX
and SIX6 to function as candidate transcription factors for specifying a retinal fate.
However, future studies are needed to further investigate the exact role of RAX and
SIX6 in specifying a retinal fate in human development.
4.1 hiPSCs and Translational medicine
Beyond studies of human development, hiPSCs have also been implicated to play an
important role in the field of translational medicine. They are pluripotent stem cells,
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meaning that not only do they possess the capability to self-renew but can also dif-
ferentiate into multiple cells types. Also, these have been derived from somatic cells
with important implications for patient-specific medicine. Due to these properties,
hiPSCs have been sought after in the field of regenerative medicine. hiPSCs have
been implicated to play a role in the following avenues: Cell replacement, disease
modeling, generation of patient-specific medicine and drug screening and develop-
ment (Figure 4.3).
Figure 4.3. hiPSCs have numerous applications in translational research
and therapy [45].
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Although hiPSCs demonstrate a great potential for a wide range of translational
applications, there have been some limitations to the application of this technol-
ogy [162]. One of the main limitation stems from the methods used to derive these
cells. The method used to reprogram the cells makes an important difference for fu-
ture applications of hiPSCs. Traditionally, hiPSCs were derived using retroviruses or
lentiviruses [53,54]. However, the use of viruses as vectors opens up the possibility of
their subsequent integration in the genome. Hence, vector systems employing episo-
mal vectors [56], small molecules [163], vector-less, direct delivery of reprogramming
proteins [163–165], as well as mRNA based reprogramming methods are currently
replacing the traditional methods of reprogramming.
The next hurdle is the actual reprogramming event. The reprogramming efficiency
of the non-viral methods are 1000 fold lower than those by viral methods [55], which
had already been exceeding low (approximately 0.1% efficiency). Also, in some cases,
incomplete reprogramming could lead to formation of aberrant stem cells with limited
capacity to self-renew or differentiate [166]. The external environment also plays a key
role in the reprogramming cells, as it has been demonstrated that cells respond best
to conditions of hypoxia [167] or cultures supplemented with Vitamin C [168]. Even
the diet of the donor can induce epigenetic changes in the resulting iPS cells [169].
Also, iPS cells have a high degree of variability, where some cell lines are more potent
than others [170].
After successful generation and characterization of cell lines, the next hurdle is the
actual transplantation event. iPS cells are highly variable and differ in their ability
to form teratomas upon transplantation [171]. Also, insufficient amount of cells for
transplantation, the technical difficulties of imaging the grafted cells, cell instability,
side effects such as graft rejection and lack of humanized animal models further add
to the reduced successful rate of cell replacement using hiPSCs [172].
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It is thought that the use of non-xenogeneic components can help reduce rejection
of the transplanted hiPSCs by the host [112]. In order to do so, hiPSCs must be
maintained and differentiated in a non-xenogeneic environment with no animal com-
ponents or serum. However, most methods of maintenance of hESCs and hiPSCs
involve their growth on Mouse Embryonic Fibroblasts (MEF) as feeder cells or the
use of matrigel, which is the extracellular matrix derived from mouse carcinomas [111].
Also, most differentiation protocols involve the use of FBS or KOSR in their differenti-
ation protocol [114]. The use of such components can introduce unwanted xenogeneic
components, leading to increased chances of rejection of hiPSCs upon transplanta-
tion. As an effort to remove all traces of animal components from hiPSCs, efforts
have been made to made to maintain and differentiate hiPSCs in xeno-free condi-
tions [173]. However, most studies lack in their ability to maintain a non-xenogeneic
component throughout the course of differentiation of hPSCs [134].
The studies presented here help to overcome some of the challenges associated with the
culture of hiPSCs under non-xenogenic components. First, the use of synthetically-
coated plates eliminates the use of MEF or matrigel for efficient culture of hiPSCs.
Second, the use of non-xenogeneic medium eliminates the use of animal components or
serum in the medium, which is an improvement over the traditional methods. Hence,
a non-xenogeneic environment was maintained by ensuring that all components used
at every stage of culture of hiPSCs were devoid of any animal component or serum.
Beyond the growth of hiPSCs under non-xenogeneic conditions, it remained to be
demonstrated that these cells could be effectively differentiated to a retinal fate.
Thus, the cells were directed to differentiate with appropriate modifications to pro-
tocols previously established within the Meyer lab. Cells grown in a non-xenogeneic
environment expressed an similarl compliment of transcription factors when compared
to the hiPSCs grown on MEF and feeder-free systems (Figure 3.2A-H). At day 10
of differentiation, they acquired makers of the anterior neuroepithelium, with PAX6
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being the main initiator of this stage [21]. Additionally, a full set of EFTFs were also
expressed at this stage (Figure 3.2H). Interestingly, immature neural rosettes were
also seen at this stage, which stained positive for SOX1 (Figure 3.1A). The absence
of mid brain and hind brain markers at this stage further confirms the anterior neural
identity of these cells (Figure 3.2H).
At day 20 of differentiation, the cells organized themselves into two populations;
retinal progenitor cells and non-retinal cells (Figure 3.3A). The retinal progenitors
were identified by a lighter ring on the outside while the non-retinal cells lacked that
morphological feature, as had been previously demonstrated for retinal differentia-
tion under transitional systems [117]. Additionally, hiPSCs grown in the xeno-free
medium gave rise to a slightly reduced number of retinal progenitors (about 15% reti-
nal progenitors from a mixed population) from a mixed population when compared to
MEF and feeder-free systems (20% efficiency) [93]. However, after this stage, almost
all retinal progenitors developed into mature retinal cells, irrespective of the system
they were grown in.
Further differentiation of hiPSC-derived retinal progenitors cells led to the expression
of photoreceptor precursor markers like CRX at 50 days of differentiation. Cells rem-
iniscent of the photoreceptor morphology were present in all three systems analyzed.
Also, hiPSCs grown in non-xenogeneic conditions produced RPE robustly, with cells
that became deeply pigmented and hexagonal in shape and expressed a full set of
transcription factors specific to the RPE. This is particularly interesting as current
efforts in the iPS field have been related to transplantation of RPE [104, 119, 174].
As our protocol highlights an efficient method to derive RPE spontaneously in a
xeno-free environment, these cells can be further used for generating RPE cells for
transplantation.
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Previous efforts to derive RPE in a non-xenogeneic environment used FBS in their
protocol, raising doubts of the true non-xenogeneic potential of these cells [124]. This
is the first demonstrations of deriving retinal cells from hiPSCs under a xeno-free en-
vironment where care has been taken to ensure that all products are non-xenogeneic.
Previous studies have generated clinical grade cell lines from hESCs [131]. These lines
could be then be used to derive retinal cells using our protocol in future.
In summary, hiPSCs provide a unique model to recapitulate retinogenesis in vitro
and function as a valuable tool for studies related to human development. Human
iPS cells can be effectively specified towards a retinal lineage under conditions that
underscore the applicability of hiPS cells for potential translational applications. Also,
human iPS cell-derived retinal populations have the potential to be used in many
applications, including transplantation, drug screening, and as a model for human
retinal development and disease. In future, hiPSCs can be directed to generate more
retinal cells in vitro to warrant effective cell replacement in diseases that affect the
retina, including glaucoma and age-related macular degeneration.
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